Ldl-lowering therapies

Ldl-lowering therapies has been studied in 2 papers since 2023: none in people yet, 2 reviews; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 31, 2026: “Atherogenic lipoprotein particles and premature coronary artery disease: from molecular mechanisms to precision prevention”.

Intervention

2 papers study it1 findingUpdated

1 new paper in 30 daysSee all 2 papers on ldl-lowering therapies

What did studies of ldl-lowering therapies find?

1

Studies of ldl-lowering therapies measured one outcome, cardiovascular events.

Cardiovascular events

downin humans1

1 study
  1. Ldl-lowering therapies decrease cardiovascular events in humans.

    “LDL-lowering therapies have established cardiovascular outcome efficacy.”

    Review

    Atherogenic lipoprotein particles and premature coronary artery disease: from molecular mechanisms to precision prevention

    Frontiers in cardiovascular medicine

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months